Glutamate decarboxylase explained

glutamate decarboxylase
Ec Number:4.1.1.15
Cas Number:9024-58-2m
Go Code:0004351
Glutamic acid decarboxylase 1
Caption:GAD67 derived from
Hgncid:4092
Symbol:GAD1
Altsymbols:glutamate decarboxylase 1
(brain, 67kD); GAD67
Entrezgene:2571
Omim:605363
Refseq:NM_000817
Uniprot:Q99259
Ecnumber:4.1.1.15
Chromosome:2
Arm:q
Band:31
glutamic acid decarboxylase 2
Hgncid:11284
Symbol:GAD2
Altsymbols:GAD65
Entrezgene:2572
Omim:4093
Refseq:NM_001047
Uniprot:Q05329
Ecnumber:4.1.1.15
Chromosome:10
Arm:p
Band:11.23

Glutamate decarboxylase or glutamic acid decarboxylase (GAD) is an enzyme that catalyzes the decarboxylation of glutamate to gamma-aminobutyric acid (GABA) and carbon dioxide . GAD uses pyridoxal-phosphate (PLP) as a cofactor. The reaction proceeds as follows:

In mammals, GAD exists in two isoforms with molecular weights of 67 and 65 kDa (GAD67 and GAD65), which are encoded by two different genes on different chromosomes (GAD1 and GAD2 genes, chromosomes 2 and 10 in humans, respectively).[1] [2] GAD67 and GAD65 are expressed in the brain where GABA is used as a neurotransmitter, and they are also expressed in the insulin-producing β-cells of the pancreas, in varying ratios depending upon the species.[3] Together, these two enzymes maintain the major physiological supply of GABA in mammals,[2] though it may also be synthesized from putrescine in the enteric nervous system,[4] brain,[5] [6] and elsewhere by the actions of diamine oxidase and aldehyde dehydrogenase 1a1.

Several truncated transcripts and polypeptides of GAD67 are detectable in the developing brain,[7] however their function, if any, is unknown.

Structure and mechanism

Both isoforms of GAD are homodimeric structures, consisting of three primary domains: the PLP, C-terminal and N-terminal domains. The PLP-binding domain of this enzyme adopts a type I PLP-dependent transferase-like fold.[8] The reaction proceeds via the canonical mechanism, involving Schiff base linkage between PLP and Lys405. PLP is held in place through base-stacking with an adjacent histidine residue, and GABA is positioned such that its carboxyl group forms a salt bridge with arginine and a hydrogen bond with glutamine.

Dimerization is essential to maintaining function as the active site is found at this interface, and mutations interfering with optimal association between the 2 chains has been linked to pathology, such as schizophrenia.[9] [10] Interference of dimerization by GAD inhibitors such as 2-keto-4-pentenoic acid (KPA) and ethyl ketopentenoate (EKP) were also shown to lead to dramatic reductions in GABA production and incidence of seizures.[11] [8]

Catalytic activity is mediated by a short flexible loop at the dimer interface (residues 432–442 in GAD67, and 423–433 in GAD65). In GAD67 this loop remains tethered, covering the active site and providing a catalytic environment to sustain GABA production; its mobility in GAD65 promotes a side reaction that results in release of PLP, leading to autoinactivation. The conformation of this loop is intimately linked to the C-terminal domain, which also affects the rate of autoinactivation.[12] Moreover, GABA-bound GAD65 is intrinsically more flexible and exists as an ensemble of states, thus providing more opportunities for autoantigenicity as seen in Type 1 diabetes.[13] [14] GAD derived from Escherichia coli shows additional structural intricacies, including a pH-dependent conformational change. This behavior is defined by the presence of a triple helical bundle formed by the N-termini of the hexameric protein in acidic environments.[15]

Regulation of GAD65 and GAD67

Despite an extensive sequence similarity between the two genes, GAD65 and GAD67 fulfill very different roles within the human body. Additionally, research suggests that GAD65 and GAD67 are regulated by distinctly different cellular mechanisms.

GAD65 and GAD67 synthesize GABA at different locations in the cell, at different developmental times, and for functionally different purposes.[16] [17] GAD67 is spread evenly throughout the cell while GAD65 is localized to nerve terminals.[18] [19] GAD67 synthesizes GABA for neuron activity unrelated to neurotransmission, such as synaptogenesis and protection from neural injury. This function requires widespread, ubiquitous presence of GABA. GAD65, however, synthesizes GABA for neurotransmission, and therefore is only necessary at nerve terminals and synapses. In order to aid in neurotransmission, GAD65 forms a complex with heat shock cognate 70 (HSC70), cysteine string protein (CSP) and vesicular GABA transporter VGAT, which, as a complex, helps package GABA into vesicles for release during neurotransmission.[20] GAD67 is transcribed during early development, while GAD65 is not transcribed until later in life. This developmental difference in GAD67 and GAD65 reflects the functional properties of each isoform; GAD67 is needed throughout development for normal cellular functioning, while GAD65 is not needed until slightly later in development when synaptic inhibition is more prevalent.

GAD67 and GAD65 are also regulated differently post-translationally. Both GAD65 and GAD67 are regulated via phosphorylation of a dynamic catalytic loop,[21] [22] but the regulation of these isoforms differs; GAD65 is activated by phosphorylation while GAD67 is inhibited by phosphorylation. GAD67 is predominantly found activated (~92%), whereas GAD65 is predominantly found inactivated (~72%). GAD67 is phosphorylated at threonine 91 by protein kinase A (PKA), while GAD65 is phosphorylated, and therefore regulated by, protein kinase C (PKC). Both GAD67 and GAD65 are also regulated post-translationally by pyridoxal 5’-phosphate (PLP); GAD is activated when bound to PLP and inactive when not bound to PLP.[23] Majority of GAD67 is bound to PLP at any given time, whereas GAD65 binds PLP when GABA is needed for neurotransmission. This reflects the functional properties of the two isoforms; GAD67 must be active at all times for normal cellular functioning, and is therefore constantly activated by PLP, while GAD65 must only be activated when GABA neurotransmission occurs, and is therefore regulated according to the synaptic environment.

Studies with mice also show functional differences between Gad67 and Gad65. GAD67−/− mice are born with cleft palate and die within a day after birth while GAD65−/− mice survive with a slightly increased tendency in seizures. Additionally, GAD65+/- have symptoms defined similarly to attention deficit hyperactivity disorder (ADHD) in humans.[24]

Role in the nervous system

Both GAD67 and GAD65 are present in all types of synapses within the human nervous system. This includes dendrodendritic, axosomatic, and axodendritic synapses. Preliminary evidence suggests that GAD65 is dominant in the visual and neuroendocrine systems, which undergo more phasic changes. It is also believed that GAD67 is present at higher amounts in tonically active neurons.[25]

Role in pathology

Autism

Both GAD65 and GAD67 experience significant downregulation in cases of autism. In a comparison of autistic versus control brains, GAD65 and GAD67 experienced a downregulation average of 50% in parietal and cerebellar cortices of autistic brains.[26] Cerebellar Purkinje cells also reported a 40% downregulation, suggesting that affected cerebellar nuclei may disrupt output to higher order motor and cognitive areas of the brain.

Diabetes

Both GAD67 and GAD65 are targets of autoantibodies in people who later develop type 1 diabetes mellitus or latent autoimmune diabetes.[27] [28] Injections with GAD65 in ways that induce immune tolerance have been shown to prevent type 1 diabetes in rodent models.[29] [30] [31] In clinical trials, injections with GAD65 have been shown to preserve some insulin production for 30 months in humans with type 1 diabetes.[32] [33] A Cochrane systematic review also examined 1 study showing improvement of C-peptide levels in cases of Latent Autoimmune Diabetes in adults, 5 years following treatment with GAD65 .Still, it is important to highlight that the studies available to be included in this review presented considerable flaws in quality and design.[34]

Stiff person syndrome

High titers of autoantibodies to glutamic acid decarboxylase (GAD) are well documented in association with stiff person syndrome (SPS).[35] Glutamic acid decarboxylase is the rate-limiting enzyme in the synthesis of γ-aminobutyric acid (GABA), and impaired function of GABAergic neurons has been implicated in the pathogenesis of SPS. Autoantibodies to GAD might be the causative agent or a disease marker.[36]

Schizophrenia and bipolar disorder

Substantial dysregulation of GAD mRNA expression, coupled with downregulation of reelin, is observed in schizophrenia and bipolar disorder.[37] [38] The most pronounced downregulation of GAD67 was found in hippocampal stratum oriens layer in both disorders and in other layers and structures of hippocampus with varying degrees.[39]

GAD67 is a key enzyme involved in the synthesis of inhibitory neurotransmitter GABA and people with schizophrenia have been shown to express lower amounts of GAD67 in the dorsolateral prefrontal cortex compared to healthy controls.[40] The mechanism underlying the decreased levels of GAD67 in people with schizophrenia remains unclear.[41] Some have proposed that an immediate early gene, Zif268, which normally binds to the promoter region of GAD67 and increases transcription of GAD67, is lower in schizophrenic patients, thus contributing to decreased levels of GAD67.[40] Since the dorsolateral prefrontal cortex (DLPFC) is involved in working memory, and GAD67 and Zif268 mRNA levels are lower in the DLPFC of schizophrenic patients, this molecular alteration may account, at least in part, for the working memory impairments associated with the disease.

Parkinson disease

The bilateral delivery of glutamic acid decarboxylase (GAD) by an adeno-associated viral vector into the subthalamic nucleus of patients between 30 and 75 years of age with advanced, progressive, levodopa-responsive Parkinson disease resulted in significant improvement over baseline during the course of a six-month study.[42]

Cerebellar disorders

Intracerebellar administration of GAD autoantibodies to animals increases the excitability of motoneurons and impairs the production of nitric oxide (NO), a molecule involved in learning. Epitope recognition contributes to cerebellar involvement.[43] Reduced GABA levels increase glutamate levels as a consequence of lower inhibition of subtypes of GABA receptors. Higher glutamate levels activate microglia and activation of xc(−) increases the extracellular glutamate release.[44]

Neuropathic pain

Peripheral nerve injury of the sciatic nerve (a neuropathic pain model) induces a transient loss of GAD65 immunoreactive terminals in the spinal cord dorsal horn and suggests a potential involvement for these alterations in the development and amelioration of pain behaviour.[45]

Other anti-GAD-associated neurologic disorders

Antibodies directed against glutamic acid decarboxylase (GAD) are increasingly found in patients with other symptoms indicative of central nervous system (CNS) dysfunction, such as ataxia, progressive encephalomyelitis with rigidity and myoclonus (PERM), limbic encephalitis, and epilepsy.[46] The pattern of anti-GAD antibodies in epilepsy differs from type 1 diabetes and stiff-person syndrome.[47]

Role of glutamate decarboxylase in other organisms

Besides the synthesis of GABA, GAD has additional functions and structural variations that are organism-dependent. In Saccharomyces cerevisiae, GAD binds the Ca2+ regulatory protein calmodulin (CaM) and is also involved in responding to oxidative stress.[48] Similarly, GAD in plants binds calmodulin as well.[49] This interaction occurs at the 30-50bp CAM-binding domain (CaMBD) in its C terminus and is necessary for proper regulation of GABA production.[50] Unlike vertebrates and invertebrates, the GABA produced by GAD is used in plants to signal abiotic stress by controlling levels of intracellular Ca2+ via CaM. Binding to CaM opens Ca2+ channels and leads to an increase in Ca2+ concentrations in the cytosol, allowing Ca2+ to act as a secondary messenger and activate downstream pathways. When GAD is not bound to CaM, the CaMBD acts as an autoinhibitory domain, thus deactivating GAD in the absence of stress.[50] Interesting, in two plant species, rice and apples, Ca2+ /CAM-independent GAD isoforms have been discovered.[51] [52] The C-terminus of these isoforms contain substitutions at key residues necessary to interact with CaM in the CaMBD, preventing the protein from binding to GAD. Whereas CaMBD of the isoform in rice still functions as an autoinhibitory domain,[51] the C-terminus in the isoform in apples does not.[52] Finally, the structure of plant GAD is a hexamer and has pH-dependent activity, with the optimal pH of 5.8 in multiple species.[50] [53] but also significant activity at pH 7.3 in the presence of CaM [15]

It is also believed that the control of glutamate decarboxylase has the prospect of improving citrus produce quality post-harvest. In Citrus plants, research has shown that glutamate decarboxylase plays a key role in citrate metabolism. With the increase of glutamate decarboxylase via direct exposure, citrate levels have been seen to significantly increase within plants, and in conjunction post-harvest quality maintenance was significantly improved, and rot rates decreased.[54]

Just like GAD in plants, GAD in E. coli has a hexamer structure and is more active under acidic pH; the pH optimum for E. coli GAD is 3.8-4.6. However, unlike plants and yeast, GAD in E. coli does not require calmodulin binding to function. There are also two isoforms of GAD, namely GadA and GadB, encoded by separate genes in E. coli,[55] although both isoforms are biochemically identical.[56] The enzyme plays a major role in conferring acid resistance and allows bacteria to temporarily survive in highly acidic environments (pH < 2.5) like the stomach.[57] This is done by GAD decarboxylating glutamate to GABA, which requires H+ to be uptaken as a reactant and raises the pH inside the bacteria. GABA can then be exported out of E. coli cells and contribute to increasing the pH of the nearby extracellular environments.[15]

External links

Notes and References

  1. Erlander MG, Tillakaratne NJ, Feldblum S, Patel N, Tobin AJ . Two genes encode distinct glutamate decarboxylases . Neuron . 7 . 1 . 91–100 . July 1991 . 2069816 . 10.1016/0896-6273(91)90077-D . 15863479 .
  2. Langendorf CG, Tuck KL, Key TL, Fenalti G, Pike RN, Rosado CJ, Wong AS, Buckle AM, Law RH, Whisstock JC . 6 . Structural characterization of the mechanism through which human glutamic acid decarboxylase auto-activates . Bioscience Reports . 33 . 1 . 137–44 . January 2013 . 23126365 . 3546353 . 10.1042/BSR20120111 .
  3. Kim J, Richter W, Aanstoot HJ, Shi Y, Fu Q, Rajotte R, Warnock G, Baekkeskov S . 6 . Differential expression of GAD65 and GAD67 in human, rat, and mouse pancreatic islets . Diabetes . 42 . 12 . 1799–808 . December 1993 . 8243826 . 10.2337/diab.42.12.1799 . 29615710 .
  4. Krantis A . GABA in the Mammalian Enteric Nervous System . News in Physiological Sciences . 15 . 6 . 284–290 . December 2000 . 11390928 . 10.1152/physiologyonline.2000.15.6.284 .
  5. Sequerra EB, Gardino P, Hedin-Pereira C, de Mello FG . Putrescine as an important source of GABA in the postnatal rat subventricular zone . Neuroscience . 146 . 2 . 489–93 . May 2007 . 17395389 . 10.1016/j.neuroscience.2007.01.062 . 43003476 .
  6. Kim JI, Ganesan S, Luo SX, Wu YW, Park E, Huang EJ, Chen L, Ding JB . 6 . Aldehyde dehydrogenase 1a1 mediates a GABA synthesis pathway in midbrain dopaminergic neurons . Science . 350 . 6256 . 102–6 . October 2015 . 26430123 . 10.1126/science.aac4690 . 4725325 . 2015Sci...350..102K .
  7. Szabo G, Katarova Z, Greenspan R . Distinct protein forms are produced from alternatively spliced bicistronic glutamic acid decarboxylase mRNAs during development . Molecular and Cellular Biology . 14 . 11 . 7535–45 . November 1994 . 7935469 . 359290 . 10.1128/mcb.14.11.7535 .
  8. Reingold DF, Orlowski M . Inhibition of brain glutamate decarboxylase by 2-keto-4-pentenoic acid, a metabolite of allylglycine . J Neurochem . 32 . 3 . 907–13 . Mar 1979 . 430066 . 10.1111/j.1471-4159.1979.tb04574.x . 31823191 .
  9. Magri C, Giacopuzzi E, La Via L, Bonini D, Ravasio V, Elhussiny ME, Orizio F, Gangemi F, Valsecchi P, Bresciani R, Barbon A, Vita A, Gennarelli M . A novel homozygous mutation in GAD1 gene described in a schizophrenic patient impairs activity and dimerization of GAD67 enzyme . Sci Rep . 8 . 1 . 15470 . Oct 2018 . 30341396 . 6195539 . 10.1038/s41598-018-33924-8. 2018NatSR...815470M .
  10. Giacopuzzi E, Gennarelli M, Minelli A, Gardella R, Valsecchi P, Traversa M, Bonvicini C, Vita A, Sacchetti E, Magri C . Exome sequencing in schizophrenic patients with high levels of homozygosity identifies novel and extremely rare mutations in the GABA/glutamatergic pathways . PLOS ONE . 12 . 8 . e0182778 . Aug 2017 . 28787007 . 5546675 . 10.1371/journal.pone.0182778 . 2017PLoSO..1282778G . free .
  11. Zhang Y, Vanmeert M, Siekierska A, Ny A, John J, Callewaert G, Lescrinier E, Dehaen W, de Witte PA, Kaminski RM . Inhibition of glutamate decarboxylase (GAD) by ethyl ketopentenoate (EKP) induces treatment-resistant epileptic seizures in zebrafish . Sci Rep . 7 . 1 . 7195 . Aug 2017 . 28775328 . 5543107 . 10.1038/s41598-017-06294-w . 2017NatSR...7.7195Z .
  12. Langendorf CG, Tuck KL, Key TL, Fenalti G, Pike RN, Rosado CJ, Wong AS, Buckle AM, Law RH, Whisstock JC . Structural characterization of the mechanism through which human glutamic acid decarboxylase auto-activates . Biosci Rep . 33 . 1 . 137–44 . Jan 2013 . 23126365 . 3546353 . 10.1042/BSR20120111 .
  13. Kass I, Hoke DE, Costa MG, Reboul CF, Porebski BT, Cowieson NP, Leh H, Pennacchietti E, McCoey J, Kleifeld O, Borri Voltattorni C, Langley D, Roome B, Mackay IR, Christ D, Perahia D, Buckle M, Paiardini A, De Biase D, Buckle AM . Cofactor-dependent conformational heterogeneity of GAD65 and its role in autoimmunity and neurotransmitter homeostasis . Proc Natl Acad Sci U S A . 111 . 25 . E2524-9 . Jun 2019 . 24927554 . 4078817 . 10.1073/pnas.1403182111 . free .
  14. Ellis TM, Atkinson MA . The clinical significance of an autoimmune response against glutamic acid decarboxylase . Nat Med . 2 . 2 . 148–53 . Feb 1996 . 8574952 . 10.1038/nm0296-148 . 12788084 .
  15. Capitani G, De Biase D, Aurizi C, Gut H, Bossa F, Grütter MG . Crystal structure and functional analysis of Escherichia coli glutamate decarboxylase . EMBO J . 22 . 16 . 4027–37 . Aug 2003 . 12912902 . 175793 . 10.1093/emboj/cdg403 .
  16. Pinal CS, Tobin AJ . Uniqueness and redundancy in GABA production . Perspectives on Developmental Neurobiology . 5 . 2–3 . 109–18 . 1998 . 9777629 .
  17. Soghomonian JJ, Martin DL . Two isoforms of glutamate decarboxylase: why? . Trends in Pharmacological Sciences . 19 . 12 . 500–5 . December 1998 . 9871412 . 10.1016/s0165-6147(98)01270-x .
  18. Kaufman DL, Houser CR, Tobin AJ . Two forms of the gamma-aminobutyric acid synthetic enzyme glutamate decarboxylase have distinct intraneuronal distributions and cofactor interactions . Journal of Neurochemistry . 56 . 2 . 720–3 . February 1991 . 1988566 . 10.1111/j.1471-4159.1991.tb08211.x . 35743434 . 8194030 .
  19. Kanaani J, Cianciaruso C, Phelps EA, Pasquier M, Brioudes E, Billestrup N, Baekkeskov S . Compartmentalization of GABA synthesis by GAD67 differs between pancreatic beta cells and neurons . PLOS ONE . 10 . 2 . e0117130 . 2015 . 25647668 . 4315522 . 10.1371/journal.pone.0117130 . 2015PLoSO..1017130K . free .
  20. Jin H, Wu H, Osterhaus G, Wei J, Davis K, Sha D, Floor E, Hsu CC, Kopke RD, Wu JY . 6 . Demonstration of functional coupling between gamma -aminobutyric acid (GABA) synthesis and vesicular GABA transport into synaptic vesicles . Proceedings of the National Academy of Sciences of the United States of America . 100 . 7 . 4293–8 . April 2003 . 12634427 . 153086 . 10.1073/pnas.0730698100 . 2003PNAS..100.4293J . free .
  21. Wei J, Davis KM, Wu H, Wu JY . Protein phosphorylation of human brain glutamic acid decarboxylase (GAD)65 and GAD67 and its physiological implications . Biochemistry . 43 . 20 . 6182–9 . May 2004 . 15147202 . 10.1021/bi0496992 .
  22. Fenalti G, Law RH, Buckle AM, Langendorf C, Tuck K, Rosado CJ, Faux NG, Mahmood K, Hampe CS, Banga JP, Wilce M, Schmidberger J, Rossjohn J, El-Kabbani O, Pike RN, Smith AI, Mackay IR, Rowley MJ, Whisstock JC . 6 . GABA production by glutamic acid decarboxylase is regulated by a dynamic catalytic loop . Nature Structural & Molecular Biology . 14 . 4 . 280–6 . April 2007 . 17384644 . 10.1038/nsmb1228 . 20265911 .
  23. Battaglioli G, Liu H, Martin DL . Kinetic differences between the isoforms of glutamate decarboxylase: implications for the regulation of GABA synthesis . Journal of Neurochemistry . 86 . 4 . 879–87 . August 2003 . 12887686 . 10.1046/j.1471-4159.2003.01910.x . 23640198 .
  24. Ueno H . Enzymatic and structural aspects on glutamate decarboxylase. . Journal of Molecular Catalysis B: Enzymatic . October 2000 . 10 . 1–3 . 67–79 . 10.1016/S1381-1177(00)00114-4 .
  25. Feldblum S, Erlander MG, Tobin AJ . Different distributions of GAD65 and GAD67 mRNAs suggest that the two glutamate decarboxylases play distinctive functional roles . Journal of Neuroscience Research . 34 . 6 . 689–706 . April 1993 . 8315667 . 10.1002/jnr.490340612 . 19314092 .
  26. Fatemi SH, Halt AR, Stary JM, Kanodia R, Schulz SC, Realmuto GR . Glutamic acid decarboxylase 65 and 67 kDa proteins are reduced in autistic parietal and cerebellar cortices . en . Biological Psychiatry . 52 . 8 . 805–10 . October 2002 . 12372652 . 10.1016/S0006-3223(02)01430-0 . 30140735 .
  27. Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, Cascalho M, Folli F, Richter-Olesen H, De Camilli P, Camilli PD . Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase . Nature . 347 . 6289 . 151–6 . September 1990 . 1697648 . 10.1038/347151a0 . 1990Natur.347..151B . 4317318 .
  28. Kaufman DL, Erlander MG, Clare-Salzler M, Atkinson MA, Maclaren NK, Tobin AJ . Autoimmunity to two forms of glutamate decarboxylase in insulin-dependent diabetes mellitus . The Journal of Clinical Investigation . 89 . 1 . 283–92 . January 1992 . 1370298 . 442846 . 10.1172/JCI115573 .
  29. Tisch R, Yang XD, Singer SM, Liblau RS, Fugger L, McDevitt HO . Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice . Nature . 366 . 6450 . 72–5 . November 1993 . 8232539 . 10.1038/366072a0 . 1993Natur.366...72T . 4273636 .
  30. Kaufman DL, Clare-Salzler M, Tian J, Forsthuber T, Ting GS, Robinson P, Atkinson MA, Sercarz EE, Tobin AJ, Lehmann PV . Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes . Nature . 366 . 6450 . 69–72 . November 1993 . 7694152 . 10.1038/366069a0 . 1993Natur.366...69K . 4370149 . 8216222 .
  31. Tian J, Clare-Salzler M, Herschenfeld A, Middleton B, Newman D, Mueller R, Arita S, Evans C, Atkinson MA, Mullen Y, Sarvetnick N, Tobin AJ, Lehmann PV, Kaufman DL . Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice . Nature Medicine . 2 . 12 . 1348–53 . December 1996 . 8946834 . 10.1038/nm1296-1348 . 27692555 .
  32. Ludvigsson J, Faresjö M, Hjorth M, Axelsson S, Chéramy M, Pihl M, Vaarala O, Forsander G, Ivarsson S, Johansson C, Lindh A, Nilsson NO, Aman J, Ortqvist E, Zerhouni P, Casas R . GAD treatment and insulin secretion in recent-onset type 1 diabetes . The New England Journal of Medicine . 359 . 18 . 1909–20 . October 2008 . 18843118 . 10.1056/NEJMoa0804328 . free .
  33. Web site: Diamyd announces completion of type 1 diabetes vaccine trial with long term efficacy demonstrated at 30 months . 2008-01-28 . Press Release . Diamyd Medical AB . 2010-01-13 .
  34. Brophy . Sinead . Davies . Helen . Mannan . Sopna . Brunt . Huw . Williams . Rhys . 2011-09-07 . Interventions for latent autoimmune diabetes (LADA) in adults . Cochrane Database of Systematic Reviews . 2011 . 9 . CD006165 . 10.1002/14651858.cd006165.pub3 . 1465-1858 . 6486159 . 21901702.
  35. Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B . High-dose intravenous immune globulin for stiff-person syndrome . The New England Journal of Medicine . 345 . 26 . 1870–6 . December 2001 . 11756577 . 10.1056/NEJMoa01167 . free .
  36. Chang T, Alexopoulos H, McMenamin M, Carvajal-González A, Alexander SK, Deacon R, Erdelyi F, Szabó G, Gabor S, Lang B, Blaes F, Brown P, Vincent A . Neuronal surface and glutamic acid decarboxylase autoantibodies in Nonparaneoplastic stiff person syndrome . JAMA Neurology . 70 . 9 . 1140–9 . September 2013 . 23877118 . 10.1001/jamaneurol.2013.3499 . 6055982 .
  37. Guidotti . Alessandro . Auta . James . Davis . John M. . Gerevini . Valeria DiGiorgi . Dwivedi . Yogesh . Grayson . Dennis R. . Impagnatiello . Francesco . Pandey . Ghanshyam . Pesold . Christine . Sharma . Rajiv . Uzunov . Doncho . Costa . Erminio . Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study . Archives of General Psychiatry . 57 . 11 . 1061–1069 . 2000 . 10.1001/archpsyc.57.11.1061 . 11074872.
  38. Akbarian . Schahram . Huang . Hsien-Sung . Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders . Brain Research Reviews . 52 . 2 . 293–304 . 2006 . 10.1016/j.brainresrev.2006.04.001 . 16759710. 25771139 .
  39. Benes FM, Lim B, Matzilevich D, Walsh JP, Subburaju S, Minns M . Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars . Proceedings of the National Academy of Sciences of the United States of America . 104 . 24 . 10164–9 . June 2007 . 17553960 . 1888575 . 10.1073/pnas.0703806104 . 2007PNAS..10410164B . free .
  40. Kimoto S, Bazmi HH, Lewis DA . Lower expression of glutamic acid decarboxylase 67 in the prefrontal cortex in schizophrenia: contribution of altered regulation by Zif268 . The American Journal of Psychiatry . 171 . 9 . 969–78 . September 2014 . 24874453 . 4376371 . 10.1176/appi.ajp.2014.14010004 .
  41. Georgiev . Danko . Yoshihara . Toru . Kawabata . Rika . Matsubara . Takurou . Tsubomoto . Makoto . Minabe . Yoshio . Lewis . David A. . Hashimoto . Takanori . Cortical gene expression after a conditional knockout of 67 kDa glutamic acid decarboxylase in parvalbumin neurons . Schizophrenia Bulletin . 42 . 4 . 992–1002 . 2016 . 10.1093/schbul/sbw022 . 26980143 . 4903066 . 24197087.
  42. LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Thomas K, Sarkar A, Siddiqui MS, Tatter SB, Schwalb JM, Poston KL, Henderson JM, Kurlan RM, Richard IH, Van Meter L, Sapan CV, During MJ, Kaplitt MG, Feigin A . AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial . The Lancet. Neurology . 10 . 4 . 309–19 . April 2011 . 21419704 . 10.1016/S1474-4422(11)70039-4 . 37154043 .
  43. Manto MU, Hampe CS, Rogemond V, Honnorat J . Respective implications of glutamate decarboxylase antibodies in stiff person syndrome and cerebellar ataxia . Orphanet Journal of Rare Diseases . 6 . 3 . 3 . February 2011 . 21294897 . 3042903 . 10.1186/1750-1172-6-3 . free .
  44. Mitoma H, Manto M, Hampe CS . Pathogenic Roles of Glutamic Acid Decarboxylase 65 Autoantibodies in Cerebellar Ataxias . Journal of Immunology Research . 2017 . 2913297 . 2017-03-12 . 28386570 . 10.1155/2017/2913297 . 5366212 . free .
  45. Lorenzo LE, Magnussen C, Bailey AL, St Louis M, De Koninck Y, Ribeiro-da-Silva A . Spatial and temporal pattern of changes in the number of GAD65-immunoreactive inhibitory terminals in the rat superficial dorsal horn following peripheral nerve injury . Molecular Pain . 10 . 1 . 1744-8069-10-57 . September 2014 . 25189404 . 4164746 . 10.1186/1744-8069-10-57 . free .
  46. Dayalu P, Teener JW . Stiff Person syndrome and other anti-GAD-associated neurologic disorders . Seminars in Neurology . 32 . 5 . 544–9 . November 2012 . 23677666 . 10.1055/s-0033-1334477 . 35562171 .
  47. Liimatainen S, Honnorat J, Pittock SJ, McKeon A, Manto M, Radtke JR, Hampe CS . GAD65 autoantibody characteristics in patients with co-occurring type 1 diabetes and epilepsy may help identify underlying epilepsy etiologies . Orphanet Journal of Rare Diseases . 13 . 1 . 55 . April 2018 . 29636076 . 5892043 . 10.1186/s13023-018-0787-5 . free .
  48. Coleman ST, Fang TK, Rovinsky SA, Turano FJ, Moye-Rowley WS . Expression of a glutamate decarboxylase homologue is required for normal oxidative stress tolerance in Saccharomyces cerevisiae . J Biol Chem . 276 . 1 . 244–50 . Jan 2001 . 11031268 . 10.1074/jbc.M007103200 . free .
  49. Baum G, Lev-Yadun S, Fridmann Y, Arazi T, Katsnelson H, Zik M, Fromm H . Calmodulin binding to glutamate decarboxylase is required for regulation of glutamate and GABA metabolism and normal development in plants . EMBO J . 15 . 12 . 2988–96 . Jun 1996 . 10.1002/j.1460-2075.1996.tb00662.x . 8670800 . 450240 .
  50. Baum G, Chen Y, Arazi T, Takatsuji H, Fromm H . A plant glutamate decarboxylase containing a calmodulin binding domain. Cloning, sequence, and functional analysis . J Biol Chem . 268 . 26 . 19610–7 . Sep 1993 . 10.1016/S0021-9258(19)36560-3 . 8366104 . free .
  51. Akama K, Akihiro T, Kitagawa M, Takaiwa F . Rice (Oryza sativa) contains a novel isoform of glutamate decarboxylase that lacks an authentic calmodulin-binding domain at the C-terminus . Biochim Biophys Acta . 1522 . 3 . 143–50 . Dec 2001 . 11779628 . 10.1016/s0167-4781(01)00324-4 .
  52. Trobacher CP, Zarei A, Liu J, Clark SM, Bozzo GG, Shelp . Calmodulin-dependent and calmodulin-independent glutamate decarboxylases in apple fruit . BMC Plant Biol . 144 . 13 . Sep 2013 . 144 . 10.1186/1471-2229-13-144 . 24074460 . 3849887 . free .
  53. Zik M, Arazi T, Snedden WA, Fromm H . Two isoforms of glutamate decarboxylase in Arabidopsis are regulated by calcium/calmodulin and differ in organ distribution . Plant Mol Biol . 37 . 6 . 967–75 . Aug 1998 . 9700069 . 10.1023/a:1006047623263 . 28501096 .
  54. Sheng L, Shen D, Luo Y, Sun X, Wang J, Luo T, Zeng Y, Xu J, Deng X, Cheng Y . Exogenous γ-aminobutyric acid treatment affects citrate and amino acid accumulation to improve fruit quality and storage performance of postharvest citrus fruit . Food Chemistry . 216 . 138–45 . February 2017 . 27596402 . 10.1016/j.foodchem.2016.08.024 .
  55. Smith DK, Kassam T, Singh B, Elliott JF . Escherichia coli has two homologous glutamate decarboxylase genes that map to distinct loci . J Bacteriol . 174 . 18 . 5820–6 . Sep 1992 . 1522060 . 207112 . 10.1128/jb.174.18.5820-5826.1992 .
  56. De Biase D, Tramonti A, John RA, Bossa F . Isolation, overexpression, and biochemical characterization of the two isoforms of glutamic acid decarboxylase from Escherichia coli . Protein Expr Purif . 8 . 4 . 430–8 . Dec 1996 . 8954890 . 10.1006/prep.1996.0121 .
  57. Lin J, Lee IS, Frey J, Slonczewski JL, Foster JW . Comparative analysis of extreme acid survival in Salmonella typhimurium, Shigella flexneri, and Escherichia coli . J Bacteriol . 177 . 14 . 4097–104 . Jul 1995 . 7608084 . 177142 . 10.1128/jb.177.14.4097-4104.1995 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Glutamate decarboxylase".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.